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Abstract
The diagnosis of inflammatory breast cancer (IBC) is largely clinical and
therefore inherently somewhat subjective. The objective of this study was
to evaluate the diagnosis of IBC at two centers in North Africa where a
higher proportion of breast cancer is diagnosed as IBC than in the United
States (U.S.). Physicians prospectively enrolled suspected IBC cases at the
National Cancer Institute (NCI) – Cairo, Egypt, and the Institut Salah
Azaiz (ISA), Tunisia, recorded extent and duration of signs/symptoms of
IBC on standardized forms, and took digital photographs of the breast.
After second-level review at study hospitals, photographs and clinical infor-
mation for confirmed IBC cases were reviewed by two U.S. oncologists.
We calculated percent agreement between study hospital and U.S. oncolo-
gist diagnoses. Among cases confirmed by at least one U.S. oncologist, we
calculated median extent and duration of signs and Spearman correlations.
At least one U.S. oncologist confirmed the IBC diagnosis for 69% (39/50)
of cases with photographs at the NCI-Cairo and 88% (21/24) of cases at
the ISA. All confirmed cases had at least one sign of IBC (erythema,
edema, peau d’orange) that covered at least one-third of the breast. The
median duration of signs ranged from 1 to 3 months; extent and duration
of signs were not statistically significantly correlated. From the above-men-
tioned outcomes, it can be concluded that the diagnosis of a substantial
proportion of IBC cases is unambiguous, but a subset is difficult to distin-
guish from other types of locally advanced breast cancer. Among confirmed
cases, the extent of signs was not related to delay in diagnosis.
Introduction
Inflammatory breast cancer (IBC) is a rare, aggressive
form of breast cancer characterized by the rapid clinical
appearance of erythema (redness), edema, and peau
d’orange of the breast thought to result from the pres-
ence of tumor emboli in the breast dermal lymphatics.
The diagnosis of IBC is primarily clinical; however, a
tissue diagnosis is still necessary to establish invasive
breast cancer. The extent and duration of clinical signs
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required for IBC has not been well standardized [1]; the
seventh edition of the American Joint Committee on
Cancer (AJCC) suggests that diffuse erythema and
edema (peau d’orange) should involve a third or more
of the breast [2]. Neglected locally advanced breast can-
cers presenting late in the course of disease are not to
be considered IBC [2].
Inflammatory breast cancer has been reported to
constitute a larger proportion of breast cancers in North
Africa than in the United States (U.S.) [3, 4], although
the proportion of IBC in some parts of North Africa
appears to be declining [5]. Because the diagnosis of
IBC is largely clinical and therefore inherently somewhat
subjective, it may be difficult to distinguish IBC from
other types of locally advanced breast cancers, particu-
larly in areas such as North Africa where the majority of
breast cancers are diagnosed at an advanced stage [6–8].
Therefore, we undertook a pilot study to prospectively
assess the diagnostic criteria for IBC at two major cancer
centers in North Africa, the National Cancer Institute
(NCI) – Cairo, Egypt, and the Institut Salah Azaiz in
Tunisia, with further review via photographs and clinical
information by two oncologists in the U.S. We present
detailed information on signs/symptoms associated with
IBC and their duration. To our knowledge, this is the
first such prospective and systematic assessment of the
diagnosis of IBC using photographs and external review.
Previous assessments of the diagnosis of IBC in North
Africa have relied on retrospectively reviewed informa-
tion provided in medical records [3, 5].
Materials and Methods
Female breast cancer cases exhibiting erythema, edema, or
peau d’orange and determined to be IBC by examining
physicians in two of three oncology clinics in the Depart-
ment of Medical Oncology (NCI-Cairo) between February
12 and September 28, 2005, and the Department of
Surgery at the Institut Salah Azaiz, Tunis, Tunisia (ISA),
from January 31 to October 25, 2005, were enrolled in a
study to systematically record their clinical characteristics
before treatment. All cases were diagnosed pathologically
as breast cancer. Standardized forms were used by the cli-
nicians to record the presence, extent, and duration of
erythema, edema, peau d’orange, ulceration, tumor size,
and other clinical signs and symptoms at the time of
patient examination. Patients were also asked to consent
to digital photographs of the breast. Cases at NCI-Cairo
were further reviewed by a senior clinician to verify IBC
status, whereas cases at the ISA were reviewed and
verified as IBC during weekly cancer committee meetings.
To further assess the IBC diagnosis, two physicians in
the U.S. (SMS and SM) with expertise in IBC examined
digital photographs of the breast in conjunction with
clinical information. The U.S. physicians were board cer-
tified in oncology and experienced in evaluating patients
with all forms of breast cancer and IBC in particular.
They evaluated the photographs for characteristics of
IBC, such as presence of erythema, edema, and peau
d’orange, and used their clinical judgment to distinguish
these signs from those associated with other types of
locally advanced breast cancer [9]. IRB approval for the
study was obtained from the NCI-U.S. and participating
institutions.
Using SAS version 9.2 (SAS Institute, Inc., Cary, NC),
we calculated Spearman rank correlation coefficients (r)
and derived P-values from the t-statistic
t ¼ rð ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiðn 2Þp Þ= ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffið1 r2Þp , which were compared to
critical values of the t-distribution with n  2 degrees of
freedom [10]. A two-sided P-value  0.05 was considered
statistically significant.
Results
Concordance between study hospital
diagnosis and U.S. review
The accrual of cases in the study is shown in Figure 1. A
total of 64 breast cancers seen at the NCI-Cairo during
the study period were initially classified as IBC; 50 (78%)
were confirmed as IBC upon second-level review at the
NCI-Cairo. Digital photographs were obtained for 39 of
these 50 cases (78%), of which 27 (69%) were considered
to be IBC by at least one of two physician reviewers in
the U.S. and 17 (44%) were considered IBC by both U.S.
reviewers. A total of 24 breast cancer cases were identified
as IBC by physicians at the Institut Salah Azaiz in Tunisia
during the study period. All 24 were confirmed as IBC
upon second-level review at the ISA. Photographs were
available for all 24 cases; 21 (88%) were considered to be
IBC by at least one of two reviewers in the U.S., and 18
of the 24 (75%) were considered IBC by both U.S.
reviewers.
Photographs of selected cases are shown in Figure 2,
including two cases that all raters, including the two U.S.
oncologists, considered to be IBC (Fig. 2a and b), one
case considered to be IBC by the study hospital but
considered to be ambiguous by the U.S. oncologists due
to the absence of extensive redness (Fig. 2c), and one
case considered to be IBC by the study hospital, but
considered to be a neglected non-IBC locally advanced
breast cancer by both U.S. raters (Fig. 2d).
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27 included based on 
photographic review
12 excluded: not 
considered IBC by at 
least one U.S. 
reviewer
National Cancer Institute-Cairo
11 excluded:  no 
photographs available
3 excluded: not 
considered IBC by at 
least one U.S. 
reviewer
14 excluded: not 
considered IBC after 
review at NCI-Cairo
50 confirmed by NCI-
Cairo
Figure 1. Criteria for study inclusion.
(a) (b)
(c) (d)
Figure 2. (a) All raters agreed that this is an inflammatory breast cancer (IBC) case; erythema (50%), edema (60%), and peau d’orange (80%) of
the left breast, no tumor mass, duration of signs is 2 weeks. (b) All raters agreed this is an IBC case; erythema (60%), edema (80%), and peau
d’orange (80%) of the right breast, no tumor mass, duration of signs is 1 month; (c). Study hospital considered this an IBC case; one U.S. rater
agreed, the other did not; erythema (10%), edema (40%), peau d’orange (40%) of the left breast, duration of signs is 12 months. (d) Study
hospital considered this an IBC case; both U.S. raters did not; erythema (60%), edema (100%), peau d’orange (100%) of the right breast,
duration of signs 72 months. Percentages of the breast covered by redness, edema, and peau d’orange are based on the clinical examination
form completed by the study hospital physicians.
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Characteristics of cases designated as IBC by
study hospital and at least one U.S.
reviewer
Subsequent analyses are limited to the 27 cases at the
NCI-Cairo and 21 cases at the ISA considered to be IBC
after second level of review at the study institutions in
North Africa as well as by at least one U.S. reviewer.
The mean age at diagnosis of IBC cases was 50.3 years at
the NCI-Cairo and 47.8 years at the ISA. Other character-
istics of the IBC cases are shown in Table 1. The vast
majority of cases at both study sites had erythema, edema,
and peau d’orange of the breast, swollen axillary lymph
nodes, breast warmth, ridges/thickening of the breast, and
flattened/inverted nipples. A higher percentage of cases at
the NCI-Cairo had an underlying tumor mass, pain/
tenderness, itching/pruritis, or change in the color/
texture of the areola. Only a few cases at either center
had ulceration of the breast or nipple discharge. The
median percent of the breast presenting with erythema,
edema, and peau d’orange was 60% or greater at both
study hospitals. All cases had at least one sign of IBC
(erythema, edema, peau d’orange) that covered approxi-
mately one-third or more of the breast, consistent with
the definition of IBC in the seventh edition of the AJCC
(Table 2) [2].
The median duration of these signs was 2.5–3 months
in Egypt and 1–1.5 months in Tunisia. The physician-
reported extent of signs (erythema, edema, and peau
d’orange) and patient-reported duration of these signs
were not significantly correlated (Table 2). Although not
statistically significant, many of the correlations were
negative, suggesting that those with more extensive redness,
edema, and peau d’orange sought medical care earlier.
Positive correlations between the extent of erythema,
edema, and peau d’orange were significant or approached
statistical significance among NCI-Cairo cases; among ISA
cases, only the extent of edema and peau d’orange were
significantly positively correlated (Table 3).
Among the 85% of NCI-Cairo cases with a mass, the
median clinically determined tumor size was 8.0 cm
(range 4–16 cm). Tumor size was not significantly corre-
lated with extent of erythema (r = 0.29, P = 0.19), edema
(r = 0.07, P = 0.75), or peau d’orange (r = 0.009,
P = 0.97; data not shown in Table 3).
Results were not materially different when cases with-
out photographs were included or cases with ulceration
(which is sometimes associated with neglected breast can-
cer) were deleted. Further restriction of cases to those
determined to be IBC by both U.S. reviewers resulted in a







Total cases 27 (100) 21 (100)
Menopausal status
Premenopausal 12 (44) 13 (65)1
Perimenopausal 1 (4)
Postmenopausal 14 (52) 7 (35)
Erythema 26 (96) 19 (90)
Edema 26 (96) 20 (95)
Peau d’orange 24 (89)1 18 (86)
Mass 22 (85)1 1 (5)1
Ulceration 4 (15) 1 (5)1
Swollen axillary nodes 26 (96) 18 (86)
Breast painful/tender 22 (81) 5 (24)
Breast warm 24 (89) 17 (81)
Breast itching/pruritis 19 (70) 12 (57)
Nipple discharge 5 (19) 01
Ridges/thickening of breast 22 (81) 19 (90)
Nipple flattened/inverted 25 (93) 20 (95)
Change in color/texture of areola 21 (78) 12 (57)
1Missing data for one subject; percentage of those with known data.
Table 2. Extent and duration of signs of erythema, edema, and peau d’orange.
Sign
Extent of sign (% of breast)
median (range)
Duration of sign (months)
median (range)
Spearman correlation of
extent and duration of signs P-value for correlation statistic
National Cancer Institute – Cairo
Erythema 70 (10–100)1 3.0 (0.5–13.0)1 0.051 0.80
Edema 70 (20–100)1 2.5 (0.5–13.0)1 0.151 0.47
Peau d’orange 70 (30–100)2 3.0 (0.5–13.0)2 0.022 0.92
Institut Salah Azaiz
Erythema 60 (10–80)3 1.0 (0.5–12.0)2 0.192 0.45
Edema 70 (40–90) 1.5 (0.5–9.0)3 0.452 0.05
Peau d’orange 70 (50–90)3 1.5 (0.5–9.0)2 0.252 0.32
1Missing data for one subject.
2Missing data for three subjects.
3Missing data for two subjects.
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statistically significant negative correlation between dura-
tion and extent of edema for cases from the ISA
(r = 0.73, P = 0.0014).
Characteristics of cases designated as IBC by
study hospital but not by at least one U.S.
reviewer
The median age of the 12 cases considered to be IBC by
the NCI-Cairo, but not by at least one U.S. clinician, was
61 years. The median percentages of the breast covered
by redness, edema, and peau d’orange were 45, 60, and
55, respectively, and the median duration of signs was
12 months (range 0.5–72 months). All had a tumor mass.
Median tumor size was 8.0 cm. Fifty-eight percent had
ulcerations of the breast.
The median age of the three cases excluded at the ISA
was 47 years. The median percentages of the breast covered
by redness, edema, and peau d’orange were 100, 70, and
60, and the median duration of signs was 1–1.5 months
(maximum 7 months). No cases had tumor masses. The
skin of one excluded subject showed evidence of a chronic
burn, and another subject had cancer en cuirasse.
Discussion
In this pilot study, we did a systematic review of the diag-
nosis of IBC at two hospitals in North Africa (the NCI-
Cairo, Egypt, and the ISA, Tunis, Tunisia), where a higher
proportion of breast cancers have been reported to be
IBC than in the U.S. We used digital photographs,
detailed clinical information, and multiple levels of
review.
Our study suggests that diagnostic criteria for IBC vary
among physicians and institutions. We found generally
good agreement among clinicians at the ISA in Tunisia
and the collaborating physicians in the U.S. There was
less consistency at the NCI-Cairo, with 22% of initially
suspected IBC cases not confirmed upon further review at
the study hospital; of those confirmed at the study hospi-
tal, 70% were considered to be IBC upon review in the
U.S., with the remaining 30% considered to be other
types of locally advanced breast cancers. At the NCI-
Cairo, but not the ISA, the cases not confirmed by at least
one U.S. oncologist tended to be older and to have a
longer median duration of signs and more frequent breast
ulcerations than cases that were confirmed by at least one
U.S. physician.
The confirmed cases at both study hospitals had signs
consistent with the SEER Collaborative Stage for TNM 7
codes 725, 730, and 750 for diagnosis of IBC (diagnosis
of inflammatory carcinoma with a clinical description of
erythema, edema, peau d’orange involving one-third or
more, but less than or equal to half (50%) of the skin of
the breast, involving more than 50% of the breast, and
percent of breast not stated, respectively) [11]. We found
no evidence that confirmed cases with more extensive
redness, edema, and peau d’orange had longer delays in
seeking health care. In fact, there was some evidence that
those with the most extensive signs sought medical atten-
tion earlier. Moreover, the median duration of signs
before medical consultation among confirmed IBC cases
in our study (1–3 months) was considerably lower than
the mean delay of 11.6 months reported among 160
patients with breast cancer showing local or T4 disease in
central Tunisia [12].
In a seminal description of clinical signs and symptoms
of 89 IBC cases, Haagensen [13] noted redness in 57% of
cases, breast enlargement in 48%, edema of the skin in
13%, a localized tumor in 57%, warmth of the skin in
8%, nipple retraction in 13%, nipple discharge in 8%,
and pain in 29%. Studies in other populations have
reported signs and symptoms that range in frequency
between Haagensen’s results and our results for the cases
from NCI-Cairo [14–17]. We are unaware of previous
studies which have linked the extent and duration of signs
in any study population.
The redness, edema, and peau d’orange characteristic
of IBC are thought to derive from the presence of
tumor emboli in the dermal lymphatic vessels [18],
although the presence of these emboli is not part of the
definition of IBC [2, 18]. In fact, a number of studies
have shown that dermal lymphatic invasion is identified
in less than 75% of IBC cases despite adequate sampling
of skin [18]. Twenty-six of the 27 NCI-Cairo IBC cases
in this analysis that were confirmed as IBC by at least
one of two reviewers in the U.S. were included in prior
publications examining the presence of tumor emboli in
the dermal lymphatics of Egyptian IBC cases [19, 20].
Forty-nine percent of these Egyptian IBC patients had
such tumor emboli; the number of tumor emboli was
Table 3. Spearman correlation coefficients (P-values) between extent
of signs of erythema, edema, and peau d’orange.
Edema Peau d’orange
National Cancer Institute – Cairo
Erythema 0.561 (0.004)* 0.392 (0.07)*
Edema 0.523 (0.01)*
Institut Salah Azaiz
Erythema 0.251 (0.30)* 0.282 (0.27)*
Edema 0.831 (<0.0001)*
1Missing data for two subjects.
2Missing data for four subjects.
3Missing data for three subjects.
*P-value.
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not associated with the number or duration of symp-
toms or tumor size. Tumor tissues from the Tunisian
cases included in this study were not available for assess-
ment of the presence of tumor emboli.
Strengths of our study include the prospective
collection of suspected IBC cases, the availability of photo-
graphs and systematically collected information on the
extent and duration of signs and symptoms, and the two
layers of review to confirm IBC diagnosis. We must note,
however, that not all cases consented to be digitally photo-
graphed and that the external review was based on photo-
graphs which were sometimes difficult to interpret. It is
also possible that the durations of signs were not accu-
rately reported by some study participants. Although the
same forms were used to collect information at both study
sites, it is possible that the signs and symptoms were inter-
preted differently at the two sites. For instance, induration
of the breast may have been considered a tumor mass in
Egypt but not Tunisia, which may partially account for the
notable difference in the percentage of cases with a tumor
mass in Egypt and Tunisia. Finally, it remains unclear how
neglected IBC can be distinguished for other types of
neglected locally advanced breast cancers.
In summary, our results suggest that the clinical diag-
nosis of a substantial proportion of IBC cases is unambig-
uous, but in certain cases, it is difficult to distinguish IBC
from other types of locally advanced breast cancer, partic-
ularly those that show extensive redness, edema, and peau
d’orange of long duration (e.g. Fig. 2d), ulcerations, or
those where it is ambiguous how much of the breast is
affected by redness, edema, and peau d’orange (e.g.
Fig. 2c). Therefore, we recommend that training to stan-
dardize IBC diagnosis, digital photographs, collection of
detailed clinical information, and several layers of review
be included in studies of IBC.
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